[PRESS RELEASE] – BOCA RATON, Fla., March 25, 2026 – Jushi Holdings Inc., a vertically integrated, multistate cannabis operator, announced that its subsidiaries Agape Total Health Care Inc., Franklin Bioscience – Penn LLC, and Franklin Bioscience – SE LLC (collectively, the “Jushi subsidiaries”) have entered into a settlement agreement and mutual release with Revelry Supply Inc. effective Feb. 11, 2026, favorably resolving claims asserted in litigation pending in the Court of Common Pleas of Philadelphia County, Pa.
The litigation, styled Agape Total Health Care Inc., et al. v. Golden Hour, LLC, et al., Civil Action No. 250803198, was filed as part of a broader enforcement action initiated by the Jushi subsidiaries against multiple entities and relates to the sale and distribution of certain unregulated intoxicating hemp-derived THC products in Pennsylvania.
As previously reported by national and industry media outlets, the company believes certain unregulated wholesalers and smoke shops are engaging in unfair trade practices by selling illegal marijuana products under the guise of “hemp.” The company believes these products are being distributed outside of the commonwealth of Pennsylvania’s regulated medical marijuana framework, providing an unlawful economic advantage to unlicensed operators, shifting compliance burdens onto lawful licenses, endangering public health, and destabilizing the regulated market.
This agreement with Revelry represents the first settlement reached in connection with that broader action.
“We initiated this litigation to help protect the integrity of state-regulated cannabis markets and, most importantly, to support public health and safety by addressing the proliferation of under-regulated intoxicating products being sold across the U.S.,” Jushi Chief Strategy Director Trent Woloveck said. “We believe consumers deserve transparency, product testing and regulatory accountability. We will continue to shine the light on the bad actors in ‘hemp.’ This first settlement marks an important step in that effort, and we remain committed to advocating for a fair, well-regulated marketplace that protects patients, consumers and stakeholders.”
The company will continue to pursue its claims against remaining defendants as appropriate in Pennsylvania and across the country.
